Post Market Clinical Follow Up
Post Market Clinical Follow Up (PMCF) is a part of the Post Market Surveillance (PMS) activities and is understood to be a continuous process that updates the Clinical Evaluation. It is carried out following the CE marking of a device.
The manufacturer should collect clinical data from the use in or on the humans after it has been commercialized or put to service within its intended purpose as referred to in the relevant conformity assessment procedure. PMCF should be done with the aim of confirming the safety and performance of the device throughout its expected lifetime. It should ensure the continued acceptability of identified risks and of detecting emerging risks on the basis of fact-based evidence.
The manufacturer must analyze the findings of the Post Market Clinical Follow Up and record the results in the Evaluation Report which should be part of the clinical evaluation report and the technical documentation. For class III and implantable devices, the evaluation report must be updated at least annually.
Purpose of Post Market Clinical Follow Up
The purpose of PMCF is as follows:
a) to gather information regarding:
-clinical observations only seen in a larger user/patient population;
-clinical observations only seen after long-term use of the device.
b) verification of clinical risk-benefit analysis conclusions.
PMCF Report and Scope of Consultants
- Identify the requirements and select the device for PMCF , specific procedures and methods
- Provides a well-defined PMCF Plan template and support develop the PMCF plan
- Review the data entered in the PMCF plan to meet the chosen PMCF objective.
- Choose the suitable method as per the characteristics and type of medical devices.
- Provides a well-defined PMCF study and report templates.
- Verifies the findings and the results based on the PMCF activity chosen by the manufacturer.
Post Market Clinical Follow Up Requirements
(A) PMCF requirements as per EU MDR 2017/745
As per the MDR, it should be carried out to proactively collect and evaluate clinical data per the method laid out in the PMCF plan which aims at:
- confirming the safety and performance throughout the expected lifetime of the device,
- identifying previously unknown side-effects and monitoring already identified side-effects and contraindications,
- identifying and analyzing emergent risks based on factual evidence,
- ensuring the continued acceptability of the benefit-risk ratio, and
- identifying possible methodical misuse or off-label use of the device, with a view to proving that the intended purpose is correct.
If through PMCF, the need for preventive and/or corrective measures has been identified, the manufacturer must implement them.
(B) PMCF requirements as per MEDDEV 2.12/2 Rev. 2
The clinical evaluation documentation must be actively updated with the data obtained from PMS. Where Post Market Clinical Follow Up is a part of Post Market Surveillance is not deemed necessary, this must be duly justified and documented (Exemption).
Post Market Clinical Follow Up Plan
As per the MDR, a PMCF plan must include, at least:
- the general methods and procedures to be applied, such as the gathering of clinical experience gained, feedback from users, screening of other sources of clinical data and of scientific literature;
- the specific methods and procedures of PMCF to be applied, that is the evaluation of suitable registers or Post market clinical studies;
- a rationale for the appropriateness of the methods and procedures referred in the above-mentioned points;
- a reference to the relevant parts of the clinical evaluation report and to the risk management;
- specific objectives to be addressed by the PMCF;
- an assessment of the clinical data relating to equivalent or similar devices;
- reference to any relevant Common Specifications, harmonized standards when used by the manufacturer, and relevant guidance and
- a comprehensive and adequately justified time schedule for PMCF activities (e.g. detailed examination of data and reporting) to be undertaken by the manufacturer.
Frequently Asked Questions
What are the conditions when above such studies might not be required?
- When the medium or long-term safety and clinical performance are already known from previous use of the device;
- Where other appropriate post-market surveillance activities would provide sufficient data to address the risks.
What are some of the cases that justify PMCF studies?
- innovation, e.g., where the design of the device, the raw materials, the principles of operation, the technology, or the medical indications are novel;
- high-risk target populations e.g. pediatrics, elderly;
- high product-related risk e.g. based on design, materials, components, invasiveness, clinical procedures;
- identification of previously unstudied subpopulations which may show different benefit/risk-ratio e.g. hip implants in different ethnic populations and so on…
State a few examples of methodologies to carry-out PMCF studies?
- the extended follow-up of patients enrolled in premarket investigations;
- a new clinical investigation;
- a review of data derived from a device registry; or
- a review of relevant retrospective data from patients previously exposed to the device.
What is the use of the Post Market Clinical Follow Up study data?
The data and conclusions derived from the Post Market Clinical study are used to providing clinical evidence for the clinical evaluation. This may result in the need to reassess whether the device continues to comply with the General Safety and Performance Requirements (GSPR). Such assessment may result in corrective or preventive actions, for example, changes to the instructions for use/labeling, changes to manufacturing processes, revision of the device design, or public health notifications.